Bambusa Therapeutics
Clinical trials sponsored by Bambusa Therapeutics, explained in plain language.
-
New drug BBT002 aims to tackle COPD and chronic sinusitis in early trial
Disease control Recruiting nowThis study tests a new drug, BBT002, in healthy volunteers and people with chronic obstructive pulmonary disease (COPD) or chronic rhinosinusitis with nasal polyps (CRSwNP). The trial is double-blind and placebo-controlled, meaning some participants get the drug and some get a du…
Phase: PHASE1 • Sponsor: Bambusa Therapeutics • Aim: Disease control
Last updated Jul 01, 2026 23:00 UTC
-
New eczema drug enters first human tests
Symptom relief Recruiting nowThis early-stage study tests a new drug called BBT001 in healthy volunteers and adults with moderate-to-severe atopic dermatitis (eczema). The main goal is to check safety and how the drug moves through the body. About 198 participants will receive either BBT001 or a placebo, wit…
Phase: PHASE1 • Sponsor: Bambusa Therapeutics • Aim: Symptom relief
Last updated Jul 01, 2026 23:00 UTC
-
New COPD drug BBT002 enters first human safety trials
Symptom relief Recruiting nowThis early-stage study tests a new drug called BBT002 in healthy people and those with COPD to see if it is safe and tolerable. Researchers will also look for early signs that it might ease breathing problems. About 68 participants will receive either the drug or a placebo, with …
Phase: PHASE1 • Sponsor: Bambusa Therapeutics • Aim: Symptom relief
Last updated Jun 27, 2026 08:08 UTC
-
New eczema drug enters first human tests
Symptom relief Recruiting nowThis early-stage study tests a new drug called BBT001 in healthy volunteers and adults with moderate-to-severe eczema (atopic dermatitis). The main goal is to check safety and how the body processes the drug. About 63 participants will receive either the drug or a placebo, with d…
Phase: PHASE1 • Sponsor: Bambusa Therapeutics • Aim: Symptom relief
Last updated Jun 27, 2026 07:59 UTC